Clinical trials: Dyslipidaemia, open to volunteers
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
The purpose of this study is to compare the effectiveness, safety of SYH2053 in participants with primary hypercholesterolemia (non-familial) or mixed dyslipidemia on a background of lipid-lowering therapy.
- Trial name
- NCT07421284
- Where
- China
- Volunteers
- 900 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Dyslipidemia, Hypertension
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C
- Trial name
- NCT07590167
- Testing
- AD-231, AD-231A, AD-231D and AD-231C
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Severe Hypertriglyceridemia
A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus…
- Trial name
- NCT07680829
- Testing
- DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule
- Where
- 2 sites in China
- Volunteers
- 378 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Familial Chylomicronemia Syndrome (FCS)
CS-121 APOC3 Base Editing in FCS
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid…
- Trial name
- NCT07176923
- Testing
- CS-121
- Where
- China
- Volunteers
- 15 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.
Mixed Dyslipidemia
A Study to Evaluate the Efficacy and Safety of AD-218
The purpose of this study is to evaluate the efficacy and safety of AD-218
- Trial name
- NCT05400317
- Testing
- AD-218, AD-218A
- Where
- South Korea
- Volunteers
- 520 people
- Sponsor
- Addpharma Inc.
Primary Hypercholesterolemia or Mixed Dyslipidemia
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
This non-interventional study is a mandatory regular Post Marketing Surveillance(rPMS) granted by the Korean health authorities, and is conducted to assess the effectiveness and safety of Leqvio® Pre-filled Syringe(inclisiran…
- Trial name
- NCT06770543
- Testing
- Inclisiran
- Where
- 4 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Participants, Hyperlipidemia
A Phase 1 Study of VELA-101 in Adult Participants
This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses…
- Trial name
- NCT07864311
- Testing
- VELA-101
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ursa Medicines
Hypercholesterolemia
A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors.
- Trial name
- NCT07404553
- Testing
- SHR-1918 Injection
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Primary Hypercholesterolemia or Mixed Hyperlipidemia
QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
To evaluate the efficacy, safety and immunogenicity of QCL7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized lipid-lowering…
- Trial name
- NCT07441317
- Testing
- QLC7401
- Volunteers
- 780 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Severe Hypertriglyceridemia
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia.
- Trial name
- SOLARIS-1 (NCT07269210)
- Testing
- Solbinsiran
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Blood Clots, Infection and Inflammatory Reaction
Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices
This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions.
- Conditions
- Blood Clots, Infection and Inflammatory Reaction, Heart Disease, Kidney Disease
- Trial name
- EVOLVE (NCT07378514)
- Testing
- Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests
- Volunteers
- 30,000 people
- Sponsor
- LumiraDx UK Limited
Hypercholesterolemia, Dyslipidemias
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
- Trial name
- PIVOTAL (NCT07083206)
- Where
- South Korea
- Volunteers
- 4,500 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Atherosclerotic Cardiovascular Disease
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with…
- Trial name
- OPTIMA (NCT07034690)
- Testing
- Educational Material, Standard of care
- Where
- United Arab Emirates
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Primary Hypercholesterolemia or Mixed Hyperlipidemia
QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy.
- Trial name
- NCT07444086
- Testing
- QLC7401
- Volunteers
- 510 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hypercholesterolemia
A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.
- Trial name
- NCT07634484
- Testing
- Pemafibrate 0.2 mg/day, Pemafibrate 0.4 mg/day
- Where
- 10 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Kowa Company, Ltd.
Hyperlipidemia, Diabete Type 2
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers
- Trial name
- NCT07730567
- Testing
- Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B)
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperlipoproteinemia
Clinical Trial On The Effect Of Artisterol On Risk Factors In Individuals With Suboptimal Cholesterol Levels
The goal of this clinical trial is to learn if Artisterol works to lower LDL cholesterol and other metabolic and vascular risk factors in adults.
- Trial name
- NCT07405814
- Testing
- investigational product containing phytosterol, artichoke extract and thiamin
- Where
- Poland
- Volunteers
- 106 people
- Sponsor
- Zentiva, k.s.
Acute Coronary Syndrome
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
This study aims to evaluate the effectiveness and safety of implementing a systematic augmented low-density lipoprotein cholesterol (LDL-C) management care pathway initiated in hospitals for patients with Acute Coronary Syndrome.
- Trial name
- NCT07684469
- Testing
- inclisiran, SOC
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolaemia
LATAM LOWERS LDL-C
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and…
- Trial name
- NCT06501443
- Testing
- Usual care, KJX839
- Where
- 11 sites in Argentina, Brazil
- Volunteers
- 520 people
- Sponsor
- Novartis Pharmaceuticals